TICKERNERD
Menu
SPRCSPRCHealthcare · Biotechnology

SPRC Stock Forecast: SciSparc Ltd. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$4.08
−8.72% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 12 Oct 2026 — in the weakest quartile.

Market cap
$103.1M
Ticker Nerd rank
20 / 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−6.4%
1M
−19.7%
YTD
−66.7%
1Y
−88.7%
From 52W high
−89.5%
From 52W low
+33.3%
$3
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SPRC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SciSparc Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
96
Momentum
35
Issuance
35
Revisions
25
Growth
18
Quality
13
Value
6
Volatility
5

Size (98): Smaller than most of the companies we track.

Volatility (5): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPRC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26SPRC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SPRC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, SciSparc Ltd. returned −88.7% against +20.4% for the S&P 500, dividends included.

SPRC vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120140Jan 26Apr 26Jul 26Oct 26SPRCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPRC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

SciSparc Ltd. (SPRC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
3.8×

Cheaper than 32% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
−1.7×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−38.4%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1720.8%

Higher than 4% of US stocks

Net margin
73.7%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−164.5%

Higher than 9% of US stocks

Return on assets
−26.0%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SciSparc Ltd. (SPRC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SciSparc Ltd. has a market value of $103.1M and an enterprise value of $8.2M.

  • Shares outstanding: 365,443.

  • Trailing P/E: 0.0×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SciSparc Ltd. employs 3 people.

market figures as at 12 Oct 2026

Data provided by Twelve Data

Peers

SPRC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRCSciSparc Ltd.$103.1M
20
SILOSilo Pharma, Inc.$2.4M
22
GNPXGenprex, Inc.$2.2M
10
BRTXBioRestorative Therapies, Inc.$2.4M
7
ELABPMGC Holdings, Inc.$2.5M
3
VRAXVirax Biolabs Group Ltd.$2.5M
16
SLXNSilexion Therapeutics Corp.$2.6M
57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SciSparc Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPRC news & analysis

SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture

GlobeNewsWire · 7 Oct 2026positive

SciSparc said its majority-owned subsidiary NeuroThera Labs reported that CliniQuantum’s GPU-accelerated quantum-simulation platform achieved approximately 16.8-fold computational acceleration versus a CPU-only implementation on the same 64-vCPU machine. The test used real-world clinical data and an S&P 500 company’s quantum architecture, according to the headline and excerpt.

Why it matters — The report concerns a technology result from a majority-owned SciSparc subsidiary and may be relevant to investors tracking the company’s activities beyond its core pharmaceutical work.

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

GlobeNewsWire · 23 Sept 2026positive

SciSparc's subsidiary NeuroThera highlighted the enhancement of its U.S. patent portfolio through a collaboration with Clearmind, covering proprietary combinations of NeuroThera's PEA technology with LSD, ketamine, and ibogaine. The patent applications target potential therapeutic applications for mental health disorders, such as depression and PTSD, as well as substance use disorders.

Why it matters — A strengthened U.S. patent portfolio through new combination-technology applications could broaden SciSparc's intellectual property protections in the mental-health and substance-use therapeutic space.

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

TheNewswire · 2 Sept 2026positive

SciSparc's subsidiary NeuroThera Labs announced it is pursuing FDA Orphan Drug Designation for SCI-110, its drug candidate for treating adults with Tourette Syndrome, and has engaged government and public affairs firm RK Strategies to strengthen its U.S. market position and visibility among federal stakeholders.

Why it matters — Securing Orphan Drug Designation could provide regulatory and market advantages for NeuroThera's lead CNS candidate, advancing a key development milestone for SciSparc's pipeline.

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

TheNewswire · 2 Sept 2026positive

SciSparc's subsidiary NeuroThera Labs announced it is pursuing FDA Orphan Drug Designation for SCI-110, its drug candidate for treating adults with Tourette Syndrome, and has engaged the government and public affairs firm RK Strategies to strengthen its U.S. market position and visibility among federal stakeholders.

Why it matters — This marks a strategic step for NewroThera toward advancing SCI-110 for adult Tourette Syndrome, potentially enhancing the subsidiary's regulatory prospects and U.S. presence.

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

GlobeNewsWire · 31 Aug 2026positive

SciSparc announced that its subsidiary NeuroThera Labs Inc. has continued advancing participant enrollment in the clinical trial evaluating its SCI-210 treatment for symptoms associated with autism spectrum disorder. The announcement updates progress on the company's investigative CNS therapy.

Why it matters — For SPRC watchers, progress in NeuroThera's SCI-210 clinical trial reflects continued development momentum for a key pipeline program within the company's subsidiary.

FAQ

Frequently asked questions about SPRC stock

How does Ticker Nerd's model rank SPRC?

As at 12 Oct 2026, SciSparc Ltd. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the SPRC stock forecast for 2030?

No analyst covering SciSparc Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRC are extrapolating price history, which says nothing about the business.

How has SPRC stock performed over the past year?

SciSparc Ltd. returned -88.7% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SciSparc Ltd. do?

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders and related conditions.

What is the latest news on SPRC?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture". SciSparc said its majority-owned subsidiary NeuroThera Labs reported that CliniQuantum’s GPU-accelerated quantum-simulation platform achieved approximately 16.8-fold computational acceleration versus a CPU-only implementation on the same 64-vCPU machine. The test used real-world clinical data and an S&P 500 company’s quantum architecture, according to the headline and excerpt.

Company

About SciSparc Ltd.

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders and related conditions. Its current pipeline includes drug candidates aimed at Tourette syndrome, Alzheimer’s disease and agitation, autism spectrum disorder, status epilepticus, obstructive sleep apnea, and chronic pain. The company’s core programs are built around proprietary formulations that combine cannabinoid compounds with palmitoylethanolamide, supporting both clinical and preclinical development efforts. SciSparc also operates commercial activities through sales of hemp seed oil-based and other hemp-derived consumer products. Based in Tel Aviv, Israel, SciSparc participates in the broader specialty pharmaceutical market by advancing targeted therapies and complementing its research pipeline with product sales and development collaborations.

CEO Mr. Oz Adler CPA · 3 employees · Israel · https://scisparc.com